Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoSeven for bleeding after stem cell transplantation
NCT01562158Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2001
- Primary completion
- Oct 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of coagulation factor VIIa in hemorrhage (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in bleeding score at 38 hours. Started Apr 2001; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT01562158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562158.